Extra-pancreatic manifestations of IgG4-related systemic disease: A single-centre experience of treatment with combined immunosuppression

Internal Medicine Journal

Volumn 43, Issue 4, 2013, Pages 417-423

  Bosco, J J ^a,c   Suan, D ^a   Varikatt, W ^a,b   Lin, M W ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Extra pancreatic; IgG4 related disease; IgG4 related systemic disease; Immunosuppression

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DELAYED DIAGNOSIS; EXOCRINE GLAND; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN G4 RELATED SYSTEMIC DISEASE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LUNG DISEASE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MAINTENANCE THERAPY; MALE; MENINGITIS; ORBIT TUMOR; PRIORITY JOURNAL; PSEUDOTUMOR; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC DISEASE;

AGED; AUTOIMMUNE DISEASES; AZATHIOPRINE; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; MALE; MIDDLE AGED; PANCREATIC DISEASES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84875665424     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2012.02964.x     Document Type: Article

References (34)

1. Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M etal. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-1315.
2. Hamano H, Arakura N, Muraki T, Ozaki Y, Kiyosawa K, Kawa S. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis. J Gastroenterol 2006; 41: 1197-1205.
3. Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23: 57-66.
4. Kamisawa T, Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14: 3948-3955.
5. Kamisawa T, Satake K. Clinical management of autoimmune pancreatitis. Adv Med Sci 2007; 52: 61-65.
6. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23: 67-71.
7. Lee FJ, Varikatt W, Kairaitis K, D'Souza F, Lin M-W. IgG4-related dacryoadenitis. Ophthalmology 2010; 117: 398.e3-3984.
8. Swan MP, Bourke MJ, Hopper AD, Kwan V, Williams SJ. Autoimmune pancreatitis: an important diagnostic consideration in obstructive jaundice due to a pancreatic mass lesion. Intern Med J 2010; 40: 720-725.
9. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A etal. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-1507.
10. Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ etal. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology 2010; 139: 140-148; quiz e12-13.
11. Chan S-K, Cheuk W, Chan K-T, Chan JKC. IgG4-related sclerosing pachymeningitis: a previously unrecognized form of central nervous system involvement in IgG4-related sclerosing disease. Am J Surg Pathol 2009; 33: 1249-1252.
12. Lindstrom KM, Cousar JB, Lopes MBS. IgG4-related meningeal disease: clinico-pathological features and proposal for diagnostic criteria. Acta Neuropathol. 2010; 120: 765-776.
13. Ebbo M, Daniel L, Pavic M, Sève P, Hamidou M, Andres E etal. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012; 91: 49-56.
14. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366: 539-551.
15. Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol 2010; 34: 1812-1819.
16. Nirula A, Glaser SM, Kalled SL, Taylora FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23: 119-124.
17. Khosroshahi A, Stone JH. IgG4-related systemic disease: the age of discovery. Curr Opin Rheumatol 2011; 23: 72-73.
18. Shimizu I, Nasu K, Sato K, Ueki H, Akahane D, Sumi M etal. Lymphadenopathy of IgG4-related sclerosing disease: three case reports and review of literature. Int J Hematol 2010; 92: 751-756.
19. Dhall D, Suriawinata AA, Tang LH, Shia J, Klimstra DS. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Hum Pathol 2010; 41: 643-652.
20. Cheuk W, Yuen HKL, Chu SYY, Chiu EKW, Lam LK, Chan JKC. Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 2008; 32: 671-681.
21. Strehl JD, Hartmann A, Agaimy A. Numerous IgG4-positive plasma cells are ubiquitous in diverse localised non-specific chronic inflammatory conditions and need to be distinguished from IgG4-related systemic disorders. J Clin Pathol 2011; 64: 237-243.
22. Nakajo M, Jinnouchi S, Fukukura Y, Tanabe H, Tateno R, Nakajo M. The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions. Eur J Nucl Med Mol Imaging 2007; 34: 2088-2095.
23. Kamisawa T. Diagnostic criteria for autoimmune pancreatitis. J Clin Gastroenterol 2008; 42: 404-407.
24. Kamisawa T, Imai M, Egawa N, Tsuruta K, Okamoto A. Serum IgG4 levels and extrapancreatic lesions in autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2008; 20: 1167-1170.
25. Chari ST, Smyrk TC, Levy MJ, Topazian MD, Takahashi N, Zhang L etal. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4: 1010-1016; quiz 934.
26. Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M etal. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40: 352-358.
27. Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol 2011; 23: 108-113.
28. Tabata T, Kamisawa T, Takuma K, Egawa N, Setoguchi K, Tsuruta K etal. Serial changes of elevated serum IgG4 levels in IgG4-related systemic disease. Intern Med 2011; 50: 69-75.
29. Maire F, Le Baleur Y, Rebours V, Vullierme MP, Couvelard A, Voitot H etal. Outcome of patients with type 1 or 2 autoimmune pancreatitis. Am J Gastroenterol 2011; 106: 151-156.
30. Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M etal. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol 2009; 104: 2295-2306.
31. Mannion M, Cron RQ. Successful treatment of pediatric IgG4 related systemic disease with mycophenolate mofetil: case report and a review of the pediatric autoimmune pancreatitis literature. Pediatr Rheumatol Online J 2011; 9: 1.
32. Merkle M, Gröne H-J. Interstitial nephritis and autoimmune pancreatitis: a case report. Int Urol Nephrol 2012; 44: 319-322.
33. Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum 2010; 62: 1755-1762.
34. Khan ML, Colby TV, Viggiano RW, Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk 2010; 10: 217-219.